other material
confidence high
sentiment positive
materiality 0.85
Madrigal reports preliminary Rezdiffra Q4 2024 net sales $100M–$103M; over 11,800 patients on therapy
MADRIGAL PHARMACEUTICALS, INC.
- Preliminary Q4 2024 Rezdiffra net sales $100M–$103M, full-year $177M–$180M.
- Year-end cash, equivalents and marketable securities ~$931M.
- Over 11,800 patients on Rezdiffra as of December 31, 2024.
- EMA decision on Rezdiffra MAA expected mid-2025; German launch targeted H2 2025.
- MAESTRO-NASH OUTCOMES trial in compensated cirrhosis fully enrolled.